Trial Profile

A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK 0482 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Gemcitabine; Paclitaxel; Pemetrexed
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Glioblastoma; Male breast cancer; Non-small cell lung cancer; Pancreatic ductal carcinoma; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man
Acronyms MK-0482-001
Sponsors Merck Sharp & Dohme

25 Jun 2025 Status changed from active, no longer recruiting to completed.
03 Jun 2025 Planned End Date changed from 25 Jun 2025 to 30 Jun 2025.
03 Jun 2025 Planned primary completion date changed from 25 Jun 2025 to 30 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com